Connect Biopharma Holdings
CNTB
56 hedge funds and large institutions have $33.1M invested in Connect Biopharma Holdings in 2026 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
67% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 9
37% more funds holding
Funds holding: 41 → 56 (+15)
2% more capital invested
Capital invested by funds: $32.4M → $33.1M (+$750K)
0.7% less ownership
Funds ownership: 22.8% → 22.1% (-0.7%)
89% less call options, than puts
Call options by funds: $5K | Put options by funds: $45K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.11M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.32M |
| 3 |
6CM
683 Capital Management
New York
|
+$933K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$654K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$546K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.06M |
| 2 |
Millennium Management
New York
|
-$1.04M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$632K |
| 4 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$554K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$428K |
CNTB Hedge Fund Activity: Q2 2026 in Review
56 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q2 2026, worth a combined $33.1M — up 2.3% from $32.4M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CNTB positions and 10 closed out — a net gain of 15 holders — while 15 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $2.11M. The largest seller was Ikarian Capital, cutting an estimated $2.06M.
- 56 institutional investors held Connect Biopharma Holdings (CNTB) as of Q2 2026, up from 41 in Q1 2026.
- Funds reported $33.1M of Connect Biopharma Holdings stock for Q2 2026, up 2.3% quarter-over-quarter.
- 25 funds opened new Connect Biopharma Holdings positions in Q2 2026 and 10 closed out, a net change of +15 holders.
- The largest Connect Biopharma Holdings buyer in Q2 2026 was BlackRock, an estimated $2.11M added.
- The largest Connect Biopharma Holdings seller in Q2 2026 was Ikarian Capital, an estimated $2.06M sold.
Based on aggregated 13F filings for Q2 2026.